A Pilot Study to Assess the Downregulation of HIV-1 Associated Chronic Inflammation in Patients With Limited Immunologic Responses When Raltegravir is Added to a Virologically Suppressed HAART Regimen.
Phase of Trial: Phase III
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 11 Mar 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
- 11 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.